BNET Industries
Market Cap:$39.6M
Last Fiscal Year Sales:$168.4K
- Public
- US
Dow Jones Description
RegeneRx was formed in 1982 and is a pharmaceutical research and development company focusing on the development of products to treat a variety of human diseases. RegeneRx?s current primary business focus is the commercialization of Thymosin beta 4 (?T4?), a 43 amino acid peptide. RegeneRx is concentrating its efforts on developing a series of pharmaceutical products, based on T4, to accelerate healing and repair of diseased, damaged, and non-healing tissue and organs. Such products may also be useful in preventing damage under certain conditions. RegeneRx utilizes an outsourcing business strategy in order to effectively control costs while focusing on the clinical development of T4. RegeneRx uses this model for certain research and development, clinical trials, and manufacturing operations, as well as other functions critical to its mission. RegeneRx believes this approach enhances its ability to allocate resources rapidly to different projects. The strategy consists of (i) identifying, evaluating and licensing pharmaceutical product opportunities that appear to have a significant commercial potential; (ii) designing pre-clinical and/or clinical protocols to test such products; (iii) utilizing third party contract manufacturers to supply clinical grade material and third party contract research organizations to perform pre-clinical and/or clinical studies in accordance with its designed protocols; and (iv) pursuing sublicense arrangements with established pharmaceutical companies to support late stage clinical testing and ultimately marketing if regulatory approval is obtained.
President
JJ FinkelsteinNumber of Employees 7
Contact Information
3 Bethesda Metro Center
Suite 700
Bethesda, Maryland 20814
3019611992
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
BioWatch: Industry gears up for mid-Atlantic conference
-
RegeneRx Biopharmaceuticals announces collaboration with USAMRICD
News & Analysis
Filter by
regenerx biopharmaceuticals inc. - All News and Analysis
RegeneRx: A Beaten Down Biotech
Fritz Hottinger submits: Investors wise enough to go to cash when their stocks hit recent exit zones should now be exploring ways to recover. Major indexes and their underlying stocks will be a long time regaining previous heights; so astute investors will be looking for opportunities off the beaten paths....
RegeneRx Sponsors "Walk a Mile in My Shoes" for National Epidermolysis Bullosa Awareness Week
BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is a major sponsor of "Walk a Mile in My Shoes," the signature event of National Epidermolysis Bullosa EB Awareness Week. The "Walk a Mile in My Shoes" program coordinates events that include rallies, meetings and walk-a-thons in...
RegeneRx President and CEO to Speak at 7th Annual BIO Investor Forum
BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the 7th Annual BIO Investor Forum in San Francisco, CA, on Thursday, October 30, 2008 at 2:00 p.m. ET. To listen and view the presentation investors...
RegeneRx to Develop RGN-457 for Cystic Fibrosis
RegeneRx Seeking Strategic Partnership to Address CF in U.S. and Europe BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis CF. RGN-457 is based on thymosin beta 4...
Dr. Deepak Srivastava Joins RegeneRx Medical and Scientific Advisory Board
BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (Amex:RGN) (www.regenerx.com) reported today that Dr. Deepak Srivastava has joined RegeneRx's Medical and Scientific Advisory Board and will become a consultant to the company. Dr. Srivastava is the Director, Gladstone Institute of Cardiovascular Disease at the University of California, San Francisco, and Wilma and...
Corporate Profile for RegeneRx Biopharmaceuticals, Inc., dated Friday Nov. 15
Business Editors --BUSINESS WIRE The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. Published Date: ...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| JJ Finkelstein | President |
| Allan L Goldstein | Chief |
| C Neil Lyons | Chief Financial Officer and Treasurer |
| David Crockford | Vice President, Clinical and Regulatory Affairs |
| Claudio Cavazza | |
| Paolo Cavazza | |
| Mauro Bove | Director |
| Albert Rosenfeld | Member |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Richard J. Hindin | Chairman |
| Barrett Katz | Board of Directors |
| Deepak Srivastava | Board of Directors |
| Ewald Hannappel | Board of Directors |
| Gabriel Sosne | Board of Directors |
| Herve Byron | Board of Directors |
| Hynda K. Kleinman | Board of Directors |
| Jo-David Fine | Board of Directors |
| Joseph C. McNay | Board of Directors |
| L Thompson Bowles | Board of Directors |
| Paolo Carminati | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | President | Current |
| Maryland Angels Council | Director | Current |
Dr. Goldstein is Chairman of the Board of Directors and the Company's Chief Scientific Advisor. He is also a founder of the Company and Professor and Chairman of the Department of Biochemistry and Molecular Biology at the George Washington University School of Medicine and Health Sciences, a position he has held since 1978. Dr. Goldstein is a recognized expert in the field of immunology and protein chemistry. He is the discoverer of several important compounds, including T 1 and T 4. Dr. Goldstein has served on the editorial boards of numerous scientific and medical journals and is a member of the Board of Trustees of the Albert Sabin Vaccine Institute, the Institute for Advanced Studies in Aging and Geriatric Medicine, and the Richard B. and Lynne V. Chaney Cardiovascular Institute. Dr. Goldstein is also the author of more than 425 scientific articles and professional journals, the inventor on over fifteen U.S. patents, and the editor of several books in the field of biochemistry, biomedicine, immunology and neuroscience.
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Chief | Current |
| Irx Therapeutics, Inc. | Current | |
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| Lynne V. Cheney Cardiovascular Institute | Board Member | Current |
| Institute for Advanced Studies | Board of Directors | Current |
| Institute for Advanced Studies | President | Former |
| Regenerx Biopharmaceuticals, Inc. | Founder | Former |
| Institute for Advanced Studies | Co-Founder | Former |
| Institute for Advanced Studies | Science Director | Former |
| Regenerx Biopharmaceuticals, Inc. | Advisor | Former |
| Institute for Advanced Studies | Consultant | Former |
| University of Virginia School of Medicine | Professor of Internal Medicine and Pathology | Former |
| Supreme Court of the United States | Former | |
| Albert B. Sabin Vaccine Institute | Professor and Chairman, Dept. of Biochemistry and Molecular Biology | Former |
| Albert Einstein College | Board of Directors | Former |
| Stanford University | MD | Former |
| Rutgers University | Ph.D. | Former |
| Rutgers University | M.S. | Former |
| Wagner College | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Chief Financial Officer and Treasurer | Current |
| Skybridge Corporation | Senior Financial Executive | Current |
| Hfs, Inc. | Senior Financial Executive | Former |
| Florida Southern College | Bachelor of Science Degree | Former |
Mr. Crockford is RegeneRx?s Vice President, Clinical and Regulatory Affairs. He has more than 25 years of experience in the biotechnology and pharmaceutical industries. During his career as a clinical and regulatory affairs professional, Mr. Crockford established strategic plans, implemented and obtained marketing approval for eighteen drug products, including one of the first human growth hormone preparations sold in the U.S., seventeen in vitro diagnostic tests, and an intraoperative medical device to detect and treat cancer. Other clinical and regulatory achievements credited to Mr. Crockford include the cost-effective and timely development of a number of innovative investigational drugs. Mr. Crockford has a number of publications and holds more than a dozen patents.
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Vice President, Clinical and Regulatory Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Current |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Current |
Mr. Hindin is a member of the Board of Directors, having been elected in 2002. He is President and CEO of Adworks Inc., a Washington, D.C. based advertising and marketing firm having revenues in excess of $80 million annually. He is also Founder of Chicken Out Rotisserie Inc., which operates 29 restaurants in four states and the District of Columbia, with annual sales in excess of $35 million. In 1967, he co-founded Britches of Georgetowne, Inc., a clothing retailer specializing in the sale of upscale men's and women's apparel and accessories. Under his stewardship as its President and CEO, Britches became a chain of 77 units in seven states with annual sales exceeding $120 million. Currently, Mr. Hindin serves as Chairman of the Board of The Institute of Advanced Studies in Immunology and Geriatric Medicine, a non-profit 501(c)(3) corporation that specializes in disseminating medical information to the public, as well as providing the pharmaceutical industry with an independent source for testing vaccines and drugs for the elderly.
| Organization | Position | Status |
|---|---|---|
| ADWORKS, Inc. | CEO | Current |
| ADWORKS, Inc. | President | Current |
| District of Columbia, LLC | Founder | Current |
| Institute for Advanced Studies | Chairman of the Board of Directors | Current |
| Institute of Advanced Studies | Chairman of the Board | Current |
| Regenerx Biopharmaceuticals, Inc. | Chairman | Current |
| District of Columbia, LLC | Director | Current |
| Regenerx Biopharmaceuticals, Inc. | Director | Former |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Essex Investment Management Company, LLC | Chief Investment Officer | Current |
| Essex Investment Management Company, LLC | Chairman | Current |
| M.P.S.I., Inc. | Board of Directors | Current |
| Boston Ballet Inc. | Board of Directors | Current |
| Simmons College | Board of Trustees | Current |
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| The Boston Security Analysts Society, Inc | Board of Directors | Current |
| The Overseer | Board of Directors | Current |
| National Public Radio Inc. | Board of Directors | Current |
| Children's Hospital | Board of Directors | Current |
| National Public Radio Inc. | Trustee | Current |
| Wharton Investment Management Conference | Chairman, CIO & Managing Principal, Essex Investment Management | Current |
| Massachusetts, Inc. | Senior Portfolio Manager | Former |
| Essex Investment Management Company, LLC | Managing Principal | Former |
| Wharton Graduate School of the University of Pennsylvania | M.B.A. | Former |
| Yale University | A.B. Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| New York University | Ph.D. | Former |
| Duke University | Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Director | Current |
| Sigma Tau | Former |
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
In 2006, Mr. Rosenfeld became an emeritus member of RegeneRx?s Board of Directors, having served on the Board since the Company?s founding in 1982. Previously, he was the former science editor of Life magazine and Saturday Review, Consultant on Future Programs for the March of Dimes Birth Defects Foundation, and an adjunct professor in the Department of Human Biological Chemistry and Genetics at the University of Texas Medical Branch, Galveston, Texas. He has received many writing awards, including the Lasker Award, with a special citation for "leadership in medical journalism," and is a frequent author and lecturer on scientific matters.
| Organization | Position | Status |
|---|---|---|
| Regenerx Biopharmaceuticals, Inc. | Member | Current |
| Regenerx Biopharmaceuticals, Inc. | Board of Directors | Current |
| The Review Company | Former |
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

